Literature DB >> 23955078

The telomere profile distinguishes two classes of genetically distinct cutaneous squamous cell carcinomas.

C Leufke1, J Leykauf1, D Krunic1, A Jauch2, H Holtgreve-Grez3, B Böhm-Steuer2, E-B Bröcker4, C Mauch5, J Utikal6, W Hartschuh7, K J Purdie8, P Boukamp1.   

Abstract

The incidence of skin cancer is increasing worldwide and cutaneous squamous cell carcinomas (SCCs) are associated with considerable morbidity and mortality, particularly in immunosuppressed individuals ('carcinomatous catastrophy'). Yet, molecular mechanisms are still insufficiently understood. Besides ultraviolet (UV)-indicative mutations, chromosomal aberrations are prominent. As telomeres are essential in preserving chromosome integrity, and telomere erosion as well as aberrant spatial telomere distribution contribute to genomic instability, we first established telomere length profiles across the whole tissue and identified normal skin (10/30) harboring discrete epidermal sites (stem cell territories) of evenly short telomeres. Precancerous actinic keratoses (AKs) (17) and SCCs (27) expressed two telomere phenotypes: (i) tissue-wide evenly short to intermediate and (ii) longer and tissue-wide heterogeneous telomere lengths, suggesting two modes of initiation, with one likely to originate in the epidermal stem cells. Although tumor histotype, location, patient gender or age failed to distinguish the two SCC telomere phenotypes, as did telomerase activity, we found a trend for a higher degree of aberrant p53 and cyclin D1 expression with long/heterogeneous telomeres. In addition, we established an association for the short/homogeneous telomeres with a simpler and the heterogeneous telomeres with a more complex karyotype correlating also with distinct chromosomal changes. SCCs (13) from renal transplant recipients displayed the same telomere dichotomy, suggesting that both telomere subtypes contribute to 'carcinomatous catastrophy' under immunosuppression by selecting for a common set (3, 9p and 17q) and subtype-specific aberrations (e.g., 6p gain, 13q loss). As a second mechanism of telomere-dependent genomic instability, we investigated changes in telomere distribution with its most severe form of telomeric aggregates (TAs). We identified a telomere length-independent but progression-dependent increase in cells with small telomere associations in AKs (17/17) and additional TAs in SCCs (24/32), basal cell carcinomas (30/31) and malignant melanomas (15/15), and provide evidence for a reactive oxygen species-dependent mechanism in this UV-induced telomere organization-dependent genomic instability.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23955078     DOI: 10.1038/onc.2013.323

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  4 in total

1.  Correlation of telomere length to malignancy potential in non-melanoma skin cancers.

Authors:  Hanae Yamada-Hishida; Yoshimasa Nobeyama; Hidemi Nakagawa
Journal:  Oncol Lett       Date:  2017-10-26       Impact factor: 2.967

2.  Three-dimensional Nuclear Telomere Organization in Multiple Myeloma.

Authors:  Ludger Klewes; Rhea Vallente; Eric Dupas; Carolin Brand; Dietrich Grün; Amanda Guffei; Chirawadee Sathitruangsak; Julius A Awe; Alexandra Kuzyk; Daniel Lichtensztejn; Pille Tammur; Tiiu Ilus; Anu Tamm; Mari Punab; Morel Rubinger; Adebayo Olujohungbe; Sabine Mai
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

Review 3.  Convergent adaptation of cellular machineries in the evolution of large body masses and long life spans.

Authors:  Eleonora Croco; Silvia Marchionni; Gianluca Storci; Massimiliano Bonafè; Claudio Franceschi; Thomas D Stamato; Christian Sell; Antonello Lorenzini
Journal:  Biogerontology       Date:  2017-06-01       Impact factor: 4.277

4.  Adverse Effects of Vemurafenib on Skin Integrity: Hyperkeratosis and Skin Cancer Initiation Due to Altered MEK/ERK-Signaling and MMP Activity.

Authors:  Marius Tham; Hans-Jürgen Stark; Anna Jauch; Catherine Harwood; Elizabeth Pavez Lorie; Petra Boukamp
Journal:  Front Oncol       Date:  2022-01-31       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.